^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF13C expression

    i
    Other names: TNFRSF13C, TNF Receptor Superfamily Member 13C, BAFFR, CD268, Tumor Necrosis Factor Receptor Superfamily Member 13C, BLyS Receptor 3, BAFF Receptor, BAFF-R, Tumor Necrosis Factor Receptor Superfamily, Member 13C, B Cell-Activating Factor Receptor, B-Cell-Activating Factor Receptor, CD268 Antigen, Prolixin, BROMIX, CVID4, BR3
    Entrez ID:
    115650
    almost2years
    IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model. (PubMed, Blood)
    Dual-antigen targeting augmented CAR T-cell secretion of engineered IL-18 and facilitated elimination of larger myeloma burdens in vivo. Our results demonstrate that combination of engineered IL-18 secretion and multi-antigen targeting can eliminate myeloma with weak antigen expression through distinct mechanisms.
    Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
    |
    IFNG (Interferon, gamma) • IL18 (Interleukin 18)
    |
    TNFRSF13C expression
    almost2years
    B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study. (PubMed, Int J Mol Sci)
    Moreover, miR-155 expression correlated with the focus score (FS), as well as BAFF-R and IL-6R expression, which were increased in primary Sjögren's disease patients and in turn related to neoplastic evolution. In conclusion, epigenetic modulation may play a crucial role in the aberrant activation of B-cells in primary Sjögren's disease, profoundly impacting the risk of NHL development.
    Journal
    |
    MIR155 (MicroRNA 155) • IL6R (Interleukin 6 receptor)
    |
    miR-155 expression • IL6 expression • TNFRSF13C expression
    2years
    BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1, N=24, Recruiting, PeproMene Bio, Inc. | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    TNFRSF13C expression
    |
    PMB-CT01
    2years
    Transgenic Mouse Model for Translational Immunotherapy Studies on Multiple Myeloma (ASH 2023)
    al. J Immunother Cancer 2023).
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL10 (Interleukin 10) • SDC1 (Syndecan 1) • ITGAM (Integrin, alpha M) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)
    |
    PD-1 expression • LAG3 expression • HAVCR2 expression • TNFRSF13C expression
    over2years
    Single Cell Multi Omics and Spatial Analysis Reveals Plasmablast Signature Malignant Cells As a Key of Intratumor Heterogeneity in Primary Central Nervous System Lymphoma (ASH 2023)
    Through the application of single-cell and spatial transcriptomic analysis, we identified a distinct subtype expressing the PBL signature gene. These findings have important therapeutic implications and provide new insights into the mechanisms of relapse in PCNSL.
    IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CARD11 (Caspase Recruitment Domain Family Member 11) • CD70 (CD70 Molecule) • SPP1 (Secreted Phosphoprotein 1) • CD27 (CD27 Molecule) • TNFSF13B (TNF Superfamily Member 13b) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • SLAMF7 (SLAM Family Member 7) • TNFSF13 (TNF Superfamily Member 13)
    |
    TNFRSF13C expression
    over2years
    Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study (ASH 2023)
    The lymphodepletion regimen consists of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day for 3 days...All CRS events resolved with 2 doses of tocilizumab given to patient #1 and 1 dose to patient #2... PMB-CT01(BAFFRCAR T cell) treatment at DL1 was safe and demonstrated potent anti-lymphoma activity with a 100% ORR (2 CR, 1 PR) in patients with poor prognosis. CRS and ICANS were all grade 1 and reversible. Enrollment is ongoing at DL2, and additional clinical and correlative analyses will be presented at the meeting.
    Clinical • P1 data • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD19 expression • TNFRSF13C expression
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • PMB-CT01
    over2years
    PMB-BAFFR-102: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL (clinicaltrials.gov)
    P1; N=18 --> 36 | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jul 2025 --> Jul 2027
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative • TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    3years
    BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1; Trial completion date: Apr 2025 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Nov 2025
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over3years
    BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL (clinicaltrials.gov)
    P1; N=37 --> 24 | Trial completion date: Apr 2024 --> Apr 2025
    CAR T-Cell Therapy • Trial completion date • Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over3years
    PMB-BAFFR-102: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL (clinicaltrials.gov)
    P1; Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jul 2025
    CAR T-Cell Therapy • Trial completion date • Trial primary completion date
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01
    over3years
    The promoting effect of neutrophil-derived BAFF molecule on the proliferation and life span of CAL-27 oral squamous carcinoma cells. (PubMed, Immunobiology)
    In conclusion, the data presented confirm the previously suggested role of neutrophil-derived BAFF in OSCC development. The favorable effects of examined flavonoids on tumor-promoting BAFF expression in neutrophils suggest that they might be promising candidates as chemo-preventive agents in the therapy of patients with OSCC.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1) • PI3K (Phosphoinositide 3-kinases)
    |
    BCL2 expression • MCL1 expression • BAX expression • TNFRSF13C expression
    over3years
    PMB-BAFFR-102: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL (clinicaltrials.gov)
    P1; Not yet recruiting --> Recruiting
    CAR T-Cell Therapy • Enrollment open
    |
    TNFRSF13C expression
    |
    clonoSEQ
    |
    PMB-CT01